Lonza lifts forecast as performance rebounds under new strategy

23 July 2025

Swiss contract development and manufacturing group Lonza (SWX: LONN) posted a 19% rise in revenue at constant currencies to 3.6 billion Swiss francs ($4.5 billion) for the first half of 2025, driven by strong demand across its core CDMO operations. Core earnings per share rose 7% to 7.52 francs ($9.01).

Net profit jumped 29% year-on-year to 426 million francs ($511 million), with basic earnings per share up nearly 32%. The company's core CDMO business accounted for 3.1 billion francs ($3.9 billion) of total revenue, marking a 23% gain over the same period in 2024.

Growth was supported by strong utilization of mammalian drug substance production, particularly at Lonza’s Vacaville, California, site. The company noted that the large-scale facility, acquired from Roche (ROG: SIX) for $1.2 billion in 2024, performed above expectations and is expected to generate half a billion francs ($600 million) in sales this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK